Drug pipeline
Explore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Mitogen-activated protein kinase 3 (MAPK3), also known as extracellular signal-regulated kinase 1 (ERK1), is a serine/threonine kinase that serves as a critical node in the highly conserved Ras-Raf-MEK-ERK signal transduction cascade. Activated by dual phosphorylation on Thr202 and Tyr204 by upstream MEK1/2 kinases, MAPK3 translocates from the cytoplasm to the nucleus. Once in the nucleus, it phosphorylates numerous transcription factors and cytosolic substrates to regulate essential cellular processes, including cell proliferation, survival, differentiation, and apoptosis. Aberrant hyperactivation of the MAPK/ERK pathway, often driven by upstream oncogenic mutations in RAS or BRAF, is a hallmark of various malignancies, including melanoma, colorectal cancer, non-small cell lung cancer, and pancreatic cancer. Consequently, MAPK3/ERK1 represents a major therapeutic target, particularly for overcoming acquired resistance to upstream RAF and MEK inhibitors. Small-molecule inhibitors targeting MAPK3/ERK1, such as ulixertinib and temuterkib, are currently under clinical investigation to block this pathway, suppress tumor growth, and manage inflammatory conditions.
Reversible or irreversible ATP-competitive inhibition of ERK1/2 kinase activity, blocking downstream phosphorylation of substrates such as RSK and transcription factors.
6 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Mitogen-activated protein kinase 3 (MAPK3) (MAPK3).